Skip to Content

Supernus Pharmaceuticals Inc SUPN Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SUPN

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics SUPN

Company Profile SUPN

Business Description

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others. The majority of the revenue is generated from the sale of Trokendi XR.

Contact
9715 Key West Avenue
Rockville, MD, 20850
T +1 301 838-2500
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Speculative Growth
Employees 603